SAMIL PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
SAMIL PHARMACEUTICAL CO.,LTD's Market Cap is ₩1672B. At end of 2025 it was ₩2102B. Ranked #959 of 2,421 in KR market (top 40%), #491 of 781 on KOSPI (top 63%), #108 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 47%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 167.24B KRW | KR#959/2,421 Sec#108/231 |
| Revenue | 207.33B KRW | KR#1,007/2,421 Sec#58/231 |
| Net Income | -37.61B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 374.73B KRW | KR#911/2,421 Sec#54/231 |
| Net Assets | 125.55B KRW | KR#1,262/2,421 Sec#98/231 |
| Employees | 593 | KR#420/2,421 Sec#36/231 |
| Value | ||
| P/B | 1.33x | KR#1,700/2,421 Sec#115/231 |
| P/S | 0.81x | KR#1,245/2,421 Sec#68/231 |
| FCF Yield | -4.12% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -29.96% | KR#2,181/2,421 Sec#174/231 |
| ROA | -10.04% | KR#2,102/2,421 Sec#159/231 |
| Op. Margin | -13.71% | KR#2,051/2,421 Sec#138/231 |
| Revenue Growth | -4.54% | KR#1,749/2,421 Sec#166/231 |
| Financial Health | ||
| Debt Ratio | 198.47% | KR#2,098/2,421 Sec#218/231 |
| Total Debt | 174.19B KRW | KR#553/2,421 Sec#30/231 |
| FCF | -6.89B KRW | KR#1,588/2,421 Sec#129/231 |
| Cash | 6.10B KRW | KR#1,928/2,421 Sec#172/231 |
| Current Ratio | 0.48x | KR#2,156/2,421 Sec#209/231 |
| Performance | ||
| 1Y Return | -28.68% | KR#1,525/2,421 Sec#120/231 |
| 1M Return | 23.95% | KR#192/2,421 Sec#13/231 |
| From 52W High | -40.05% | KR#929/2,421 Sec#62/231 |
| 1Y MDD | -52.64% | KR#1,106/2,421 Sec#93/231 |
| Trading | ||
| Volume | 152,717 shares | KR#581/2,421 Sec#43/231 |
| Trading Value | 1.16B KRW | KR#671/2,421 Sec#68/231 |
| Foreign Own. | 3.69% | KR#1,119/2,421 Sec#102/231 |
| Per Share | ||
| EPS | -1,734 KRW | KR—/2,421 Sec—/231 |
| BPS | 5,788 KRW | KR#1,380/2,421 Sec#98/231 |
Company Info
Samil Pharmaceutical, a mid-sized pharmaceutical company established in 1947 and listed on KOSPI in 1985, primarily develops, produces, and sells specialized and generic pharmaceuticals. The company also exclusively distributes directly imported original products in Korea. It operates a subsidiary with a global ophthalmic CDMO factory in Vietnam and has secured domestic sales rights for new drugs from Galmed and Biosplice. Samil Pharmaceutical is pursuing growth in new drug development and global CDMO business, headquartered in Seocho-gu, Seoul.